Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 4
2009 1
2010 2
2011 1
2012 6
2015 1
2016 2
2017 2
2018 2
2020 5
2021 8
2022 8
2023 5
2024 9
2025 6
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean m salehi (1 results)?
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Patients received treatment until progression with carfilzomib (20 mg/m(2) on days 1 and 2 of cycle 1; 56 mg/m(2) thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1.3 mg/m(2); intravenous bolus or …
Patients received treatment until progression with carfilzomib (20 mg/m(2) on days 1 and 2 of cycle 1; 56 mg/m(2) thereafter; …
Elimination Diets in Lactating Mothers of Infants with Food Allergy.
Gelsomino M, Liotti L, Barni S, Mori F, Giovannini M, Mastrorilli C, Pecoraro L, Saretta F, Castagnoli R, Arasi S, Klain A, Giudice MMD, Novembre E. Gelsomino M, et al. Nutrients. 2024 Jul 18;16(14):2317. doi: 10.3390/nu16142317. Nutrients. 2024. PMID: 39064760 Free PMC article. Review.
Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology.
Valerio G, Di Bonito P, Calcaterra V, Cherubini V, Corica D, De Sanctis L, Di Sessa A, Faienza MF, Fornari E, Iughetti L, Licenziati MR, Manco M, Del Giudice EM, Morandi A, Salerno M, Street ME, Umano GR, Wasniewska M, Maffeis C. Valerio G, et al. Ital J Pediatr. 2024 Oct 8;50(1):205. doi: 10.1186/s13052-024-01767-x. Ital J Pediatr. 2024. PMID: 39380079 Free PMC article. Review.
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.
De Stefano V, Passamonti F, Palandri F, Ramundo F, Rossi E, Betti S, Fagiolo L, Guglielmelli P, Abagnale DP, Pugliese N, Cattaneo D, Iurlo A, Branzanti F, Dedola A, Catellani H, Tieghi A, Basso M, Calistri E, Elli EM, Masselli E, Morsia E, Benevolo G, Breccia M, de Fazio V, Di Perna M, Marchetti M, Santoro M, Tafuri A, Castiglioni C, Rotella C, Siragusa S, Vannucchi AM; PROSPERO Study group. De Stefano V, et al. Ann Hematol. 2025 Jul;104(7):3553-3566. doi: 10.1007/s00277-025-06466-z. Epub 2025 Jul 18. Ann Hematol. 2025. PMID: 40679584 Free PMC article. Review.
Genotype-phenotype correlation in contactin-associated protein-like 2 (CNTNAP-2) developmental disorder.
D'Onofrio G, Accogli A, Severino M, Caliskan H, Kokotović T, Blazekovic A, Jercic KG, Markovic S, Zigman T, Goran K, Barišić N, Duranovic V, Ban A, Borovecki F, Ramadža DP, Barić I, Fazeli W, Herkenrath P, Marini C, Vittorini R, Gowda V, Bouman A, Rocca C, Alkhawaja IA, Murtaza BN, Rehman MMU, Al Alam C, Nader G, Mancardi MM, Giacomini T, Srivastava S, Alvi JR, Tomoum H, Matricardi S, Iacomino M, Riva A, Scala M, Madia F, Pistorio A, Salpietro V, Minetti C, Rivière JB, Srour M, Efthymiou S, Maroofian R, Houlden H, Vernes SC, Zara F, Striano P, Nagy V. D'Onofrio G, et al. Hum Genet. 2023 Jul;142(7):909-925. doi: 10.1007/s00439-023-02552-2. Epub 2023 May 14. Hum Genet. 2023. PMID: 37183190 Free PMC article. Review.
We report 22 novel patients harboring mono- (n = 2) and bi-allelic (n = 20) CNTNAP2 variants and carried out a literature review to characterize the genotype-phenotype correlation. Patients (M:F 14:8) were aged between 3 and 19 years and affected by global developmental de …
We report 22 novel patients harboring mono- (n = 2) and bi-allelic (n = 20) CNTNAP2 variants and carried out a literature review to characte …
National workflow experience with pulsed field ablation for atrial fibrillation: learning curve, efficiency, and safety.
Bisignani A, Schiavone M, Solimene F, Dello Russo A, Filannino P, Magnocavallo M, Tondo C, Schillaci V, Casella M, Petretta A, Rossi P, Fassini G, Rossillo A, Maggio R, Themistoclakis S, Pandozi C, Polselli M, Tundo F, Arestia A, Compagnucci P, Valente Perrone A, Malacrida M, Iacopino S, Bianchi S. Bisignani A, et al. J Interv Card Electrophysiol. 2024 Dec;67(9):2127-2136. doi: 10.1007/s10840-024-01835-6. Epub 2024 May 30. J Interv Card Electrophysiol. 2024. PMID: 38814525 Review.
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016.
Pera MC, Coratti G, Pane M, Masson R, Sansone VA, D'Amico A, Catteruccia M, Agosto C, Varone A, Bruno C, Messina S, Ricci F, Bruno I, Procopio E, Pini A, Siliquini S, Zanin R, Albamonte E, Berardinelli A, Mastella C, Baranello G, Previtali SC, Trabacca A, Bravetti C, Gagliardi D, Filosto M, de Sanctis R, Finkel R, Mercuri E; Italian SMA type I Study Group. Pera MC, et al. EClinicalMedicine. 2024 Nov 30;78:102967. doi: 10.1016/j.eclinm.2024.102967. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39687428 Free PMC article.
Pediatric idiopathic anaphylaxis: practical management from infants to adolescents.
Mori F, Saretta F, Giovannini M, Gelsomino M, Liotti L, Barni S, Mastrorilli C, Pecoraro L, Castagnoli R, Arasi S, Caminiti L, Klain A, Miraglia Del Giudice M, Novembre E. Mori F, et al. Ital J Pediatr. 2024 Aug 9;50(1):145. doi: 10.1186/s13052-024-01712-y. Ital J Pediatr. 2024. PMID: 39118168 Free PMC article. Review.
Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: A multicenter real-world study.
Cerulli Irelli E, Mazzeo A, Caraballo RH, Perulli M, Moloney PB, Peña-Ceballos J, Rubino M, Mieszczanek KM, Santangelo A, Licchetta L, De Giorgis V, Reyes Valenzuela G, Casellato S, Cesaroni E, Operto FF, Domínguez-Carral J, Ramírez-Camacho A, Ferretti A, Santangelo G, Aledo-Serrano A, Rüegger A, Mancardi MM, Prato G, Riva A, Bergonzini L, Cordelli DM, Bonanni P, Bisulli F, Di Gennaro G, Matricardi S, Striano P, Delanty N, Marini C, Battaglia D, Di Bonaventura C, Ramantani G, Gardella E; GENE‐CBD Study Group; Orsini A, Coppola A. Cerulli Irelli E, et al. Epilepsia. 2025 Jul;66(7):2253-2267. doi: 10.1111/epi.18378. Epub 2025 Mar 24. Epilepsia. 2025. PMID: 40126049 Free PMC article.
Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders.
Masciocchi S, Businaro P, Greco G, Scaranzin S, Malvaso A, Morandi C, Zardini E, Risi M, Vegezzi E, Diamanti L, Bini P, Siquilini S, Giannoccaro MP, Morelli L, Liguori R, Patti F, De Giuli V, Portaccio E, Zanetta C, Bergamoni S, Simone AM, Lanzillo R, Bruno G, Gallo A, Bisecco A, Di Filippo M, Pauri F, Toriello A, Barone P, Tazza F, Bucello S, Banfi P, Fabris M, Volonghi I, Raciti L, Vigliani MC, Bocci T, Paoletti M, Colombo E, Filippi M, Pichiecchio A, Marchioni E, Franciotta D, Gastaldi M; Neuroimmunology platform study group (PNI). Masciocchi S, et al. Neurol Neuroimmunol Neuroinflamm. 2025 Mar;12(2):e200359. doi: 10.1212/NXI.0000000000200359. Epub 2025 Jan 17. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39823554 Free PMC article.
55 results